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Preterm birth is very strongly associated with maternal/foetal inﬂammation and leads to permanent
neurological deﬁcits. These deﬁcits correlate with the severity of white matter injury, including matura-
tional arrest of oligodendrocytes and hypomyelination. Preterm birth and exposure to inﬂammation
causes hypothyroxinemia. As such, supplementation with thyroxine (T4) seems a good candidate therapy
for reducing white matter damage in preterm infants as oligodendrocyte maturation and myelination is
regulated by thyroid hormones.
We report on a model of preterm inﬂammation-induced white matter damage, in which induction of
systemic inﬂammation by exposure from P1 to P5 to interleukin-1b (IL-1b) causes oligodendrocyte
maturational arrest and hypomyelination. This model identiﬁed transient hypothyroidism and wide-
ranging dysfunction in thyroid hormone signalling pathways. To test whether a clinically relevant dose
of T4 could reduce inﬂammation-induced white matter damage we concurrently treated mice exposed
to IL-1b from P1 to P5 with T4 (20 lg/kg/day). At P10, we isolated O4-positive pre-oligodendrocytes
and gene expression analysis revealed that T4 treatment did not recover the IL-1b-induced blockade of
oligodendrocyte maturation. Moreover, at P10 and P30 immunohistochemistry for markers of oligoden-
drocyte lineage (NG2, PDGFRa and APC) and myelin (MBP) similarly indicated that T4 treatment did not
recover IL-1b-induced deﬁcits in the white matter.
In summary, in this model of preterm inﬂammation-induced white matter injury, a clinical dose of T4
had no therapeutic efﬁcacy. We suggest that additional pre-clinical trials with T4 covering the breadth
and scope of causes and outcomes of perinatal brain injury are required before we can correctly evaluate
clinical trials data and understand the potential for thyroid hormone as a widely implementable clinical
therapy.
 2013 The Authors. Published by Elsevier Inc. Open access under CC BY license.1. Introduction ing a maturational blockade (but not loss) of oligodendrocytesPremature birth often leads to lifelong sensory and motor
deﬁcits, cognitive and learning impairments and behavioural
disturbances (Arnaud et al., 2007). These neurological impairments
are typically associated with damage to the white matter, includ-(Billiards et al., 2008; Buser et al., 2012; Verney et al., 2012) and
smaller volumes on MRI (Counsell et al., 2003; Anjari et al., 2007).
Among the various factors considered to contribute to white
matter injury in preterm infants and to represent a viable thera-
peutic strategy, augmentation of thyroid hormones levels (TH) is
particularly credible approach for several reasons. These include
that up to 85% of preterm infants suffer from hypothyroidism that
can persist for several weeks after birth (Reuss et al., 1996; Leviton
et al., 1999; Simpson et al., 2005). This transient hypothyroidism of
prematurity is associated with increased risks for white matter
damage and poor long-term neurological outcome.
96 A.-L. Schang et al. / Brain, Behavior, and Immunity 37 (2014) 95–102Hypothyroidism is a consequence of prematurity (Radetti et al.,
2004), and is induced by inﬂammation in both adults and neonates
(De Felice et al., 2005). Compounding the vulnerability of the
preterm population, inﬂammation due to maternal foetal/inﬂam-
mation (such as chorioamnionitis) is a leading cause premature la-
bour (Hillier et al., 1993; Dammann and Leviton, 2004; Goldenberg
et al., 2008; Wu et al., 2009).
THs are essential for brain development due to their proliﬁc
regulation of gene expression, and even a short period of deﬁciency
during development can lead to irreversible brain damage (Berbel
et al., 2010). Supporting the idea that supplementation of TH may
be a viable neurotherapeutic strategy, T4 is a potent inducer of oli-
godendrocyte maturation and (re)myelinationin in animal models
of demyelination and in vitro (Gravel and Hawkes, 1990; Baas et al.,
1997; Jones et al., 2003; Lin et al., 2011; Dugas et al., 2012).
Three randomized clinical trials have been undertaken to test
the efﬁcacy of thyroxin (T4) supplementation in reducing neuro-
logical deﬁcits in preterm infants (Chowdhry et al., 1984; Vanhole
et al., 1997; van Wassenaer et al., 2005). The two small trials (<40
infants) demonstrated no effect of T4 treatment, but the largest
and most recent revealed subtle improvements in learning out to
ten years of age, but only for infants born below 27 weeks gesta-
tional age (van Wassenaer et al., 2005). A new randomized clinical
trial powered to test this potential gestational age-dependent ef-
fect began in 2012 (Ng et al., 2013). However, due to uncertainty
regarding the population of infants likely to beneﬁt from T4 treat-
ment and what mechanism underpins this variation, more
research is required in experimental models to understand the sit-
uations in which T4 treatment may have the greatest therapeutic
efﬁcacy. TH therapy has been trialled in experimental models of
perinatal excitotoxicity and hypoxia-ischemia (HI) (Sarkozy et al.,
2007; Hung et al., 2013). However, the efﬁcacy of TH has not been
tested in a model of preterm injury induced by inﬂammation alone,
and results obtained in this context would improve our interpreta-
tion of clinical trial data.
As such, we have utilized a model of preterm inﬂammation-in-
duced white matter injury (mice treated with interleukin-1b [IL-
1b] from postnatal day [P] 1 to 5). These animals display a
long-lasting myelination deﬁcit linked to a blockade of oligoden-
drocyte differentiation, accompanied by cognitive defects and
MRI abnormalities (Favrais et al., 2011). In this study we demon-
strate that this model recapitulates the clinically observed tran-
sient hypothyroidism observed in preterm infants and induces
wide-ranging dysregulation of expression for TH signalling and
responsive genes. Nevertheless, treatment with a clinically rele-
vant dose of T4 is unable to recover the inﬂammation-induced
white matter deﬁcits.2. Materials and methods
2.1. Animals and drug administration
Experimental protocols were approved by the institutional
guidelines of the Institut National de la Santé et de la Recherche
Scientiﬁque (Inserm) France, and met the guidelines for the United
States Public Health Service’s Policy on Humane Care and Use of
Laboratory Animals (NIH, Bethesda, Maryland, USA). Experiments
were performed using OF1 strain mice purchased from Charles Riv-
er (L’Arbresle, France) and born in our animal facility. Animals
were housed under a 12 h light-dark cycle, had access to food
and water ad libitum and were weaned into same sex groups at
P21. On P1 pups were sexed and where necessary litters were
culled to 9–11 pups. Assessments of injury and outcomes were
made only in male animals and all pups within a litter received
identical treatment to reduce any effects of differing maternal care.IL-1b exposure was carried out as previously described (Favrais
et al., 2011). Brieﬂy, mice received twice a day from P1 to P4 and
once on P5 a 5 ll intra-peritoneal injection of 10 lg/kg/injection
recombinant mouse IL-1b in phosphate buffered saline (PBS; R&D
Systems, Minneapolis, MN) or PBS alone. For TH trials, each morn-
ing only from P1–P5 pups were co-injected with IL-1b and 20 lg/
kg/injection of T4 (T0397, Sigma-Aldrich) or at each of the 9 treat-
ments with IL-1b and 20 lg/kg/injection of Triiodthyronine (T3;
T6397, Sigma–Aldrich, Lyon, France). The dosages of T4 and T3
are similar to those used clinically (Vanhole et al., 1997; La Gamma
et al., 2009), and approximate the euthyroid dose for mice based on
previous serum measurements (Hoath et al., 1983; Mori et al.,
2006; Rodrigues et al., 2013) and a half life of T4 of 13–16 h in
the neonatal mouse (van Buul-Offers et al., 1983).
2.2. Measurements of free-T3 and free-T4 in serum
At P5 and P10, pups were decapitated and blood samples were
collected in non-heparinized tubes. Blood samples were allowed to
coagulate for 10 min at room temperature and were centrifuged
for 7 min at 4000 rpm. Sera were collected and stored at 20 C be-
fore free-T3 and free-T4 levels were measured using Siemens Advia
Centaur CP immunochemiluminescent assays (Siemens Healthcare
Diagnostics SAS, Saint-Denis, France).
2.3. Neural tissue dissociation and O4+ magnetic-activated cell sorting
At P5 and P10, brains were collected for cell dissociation and
O4-positive cell enrichment using a magnetic coupled antibody
extraction technique (MACS), as previously described and accord-
ing to the manufacturer’s protocol (Jungblut et al., 2012) (Miltenyi
Biotec, Bergisch Gladbach, Germany). The O4 antigen is expressed
on the cell surface of pre-oligodendrocytes (Back et al., 2001). In
brief, after removing the cerebellum and olfactory bulbs the brains
were pooled (n = 3 at P5 and n = 2 at P10) and dissociated using the
Neural Tissue Dissociation Kit containing papain. From the result-
ing brain homogenate O4-positive cells were enriched by MACS,
using the anti-O4 MicroBeads and after elution the isolated cells
were centrifuged for 5 min at 600g and conserved at 80 C. The
purity of the eluted O4-positive fraction was veriﬁed using qRT-
PCR for glial ﬁbrillary acid protein (GFAP), neuronal nuclear
antigen (NeuN) and ionizing calcium binding adapter protein
(Iba1) and revealed gene expression levels 95% lower than found
in the respective primary cultures of astrocytes, neurons or
microglia.
2.4. Microarray analysis and quantitative reverse-transcriptase
polymerase-chain reaction
Microarray analysis, including RNA extraction and quality
assurance, was performed by Miltenyi Biotec on a total of 24 MACS
extracted O4 enriched cell samples from P5 or P10 mice exposed to
IL-1b or PBS. Preparation of samples for array analysis and quanti-
tative reverse-transcriptase polymerase-chain reaction (qRT-PCR),
primer design, and PCR protocol, were similar to that previously
described (Husson et al., 2005; Chhor et al., 2013). Primer
sequences are given in Suppl. Table 1. Gapdh (glyceraldehyde-3-
phosphate dehydrogenase gene) was chosen to standardize the
quantitative experiments based on reference gene suitability
testing. The relative quantities are expressed as the speciﬁc ratio
between the gene of interest and Gapdh.
2.5. Immunohistochemistry and immunoﬂuorescence
AtP10, brainswerecollected forpreparationof frozen sections fol-
lowing intracardial perfusion with 4% paraformaldehyde-phosphate
Fig. 1. Serum levels of free-T3 were transiently decreased following exposure to IL-
1b. Serum levels of free-T3 were measured in PBS (white bars) and IL-1b exposed
(grey bars) P5 and P10 mouse pups. Data are shown as mean ± SEM and were
obtained with 4–11 samples per group. Asterisks indicate statistically differences
obtained by Mann–Whitney test. ⁄p < 0.05; ⁄⁄p < 0.01.
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for 4 h at room temperature and then following at least three days in
30% sucrose in PBS the brains were embedded in 15% sucrose-7.5%
gelatine solution and frozen at 80 C before sectioning at 16 lm.
At P30 brains were processed to parafﬁn sections by immediate
immersion for 6-7 days in 4% formaldehyde at room temperature
before dehydration, embedding in parafﬁn and sectioning at 12 lm.
Primary antibodies used were anti-Myelin Basic Protein (MBP,
1:500, Chemicon, Temecula, CA, USA), anti-Platelet Derived Growth
Factor Receptor-alpha (PDGFRa, 1:500, BD Biosciences, San Jose, CA,
USA), anti-Adenomatosis Polyposis Coli (APC, 1:2000, Calbiochem,
CA, USA) and anti-NG2 (1:200, Chemicon). Immunohistochemistry
and Immunoﬂuorescence staining were performed as previously de-
scribed (Favrais et al., 2011).Nucleiwere counterstained for immuno-
ﬂuorescencewithDAPI (Sigma–Aldrich).All analyseswereperformed
by an experimenter blind to treatment group. The intensity of MBP
immunostaining was assessed using densitometric analysis as previ-
ouslydescribed (Favrais et al., 2011). Cell counts forNG2, PDGFRa and
APCwereperformed in four sectionsperanimal foreachdeﬁnedbrain
structure and are expressed as the percentage of positive cells per
total number of nuclei.2.6. Statistical and microarray analysis
Quantitative data are expressed as mean ± SEM values for each
treatment group and group numbers are indicated within the text
or legends. Comparisons of results were conducted by using non-
parametric Mann–Whitney test (Prism 4.01; Graphpad Software,
San Diego, CA). The Agilent feature extraction software was used
to process microarray image ﬁles. Only signal intensities above
background were included. Signal intensity values were back-
ground subtracted and uploaded following instructions by Miltenyi
Biotec GmbH (Stefan Tomiuk) and Perkin Elmer (Matt Hudson) into
GeneSifter Analysis Edition v4.0 (http://login.genesifter.net/) for
further analysis as previously described (Gustavsson et al., 2007).
The pre-processed signal intensity values were median normalized
and the gene expression in IL-1b and PBS controls were compared
at P5 and P10 using t-test (p < 0.05) with Benjamini–Hochberg
multiple testing correction.3. Results
3.1. Perinatal systemic inﬂammation induces a transient
hypothyroidism and dysregulates thyroid signalling pathways
In mice exposed to IL-1b from P1 to P5, levels of free-T3 in the
blood at P5 were reduced by approximately 20% (Fig. 1). In PBS and
IL-1b groups, free-T3 levels increased between P5 and P10. Five
days after the cessation of IL-1b exposure at P10 there was no dif-
ference in circulating levels of free-T3 (nor free-T4, data not
shown) between PBS and IL-1b groups. Analysis of microarray data
for genes known to be involved in TH signalling and to be TH-
responsive revealed that at P5 and P10 expression of at least 42
genes were moderately but signiﬁcantly altered by IL-1b exposure
(Table 1). KEGG pathway analysis speciﬁcally revealed that TH sig-
nalling was reduced; of note, Thra, Thrb, Trhr, Trhr2, Smrte, Mct8
and Thada were decreased at P5, and at P10 expression of Thrb,
Trhr2 and Smrte was still reduced. Several genes not decreased at
P5 displayed decreased expression at P10, including Thrap3,
Thrap5, Aldh1a1 and Klf9. Several genes were also increased at both
P5 and P10 in IL-1b exposed mice, including Icosl, which is required
for thyroid follicular cell proliferation and Shh, which decreases T3
availability by actions on Gli and D3. Expression of TH-related
genes was also altered in astrocytes isolated from IL-1b exposed
mice at P5 (Supp. Fig. 1).3.2. Treatment with T4 did not recover the inﬂammation-induced
defects in oligodendrocyte maturation or myelinationin neonates or
young adults
In O4-positive cells isolated at P10 from mice exposed to IL-1b
from P1 to P5 there was increased expression of genes associated
with immature oligodendrocytes (Cnp, Pdgfra), increased expres-
sion of a negative regulator of myelination (Id2), and decreased
expression of mature oligodendrocyte markers (Mbp, Mag, Mog:
Fig. 2), in agreement with data previously reported from whole
cortex gene expression in this model. Treatment with T4 did not
reduce either these IL-1b-induced defects in oligodendrocyte mat-
urational markers nor expression of myelin genes (Fig. 2). In addi-
tion, concurrent treatment of IL-1b-exposed mice with T3 did not
recover the IL-1b induced defects in mature and immature oligo-
dendrocyte markers (Supp. Fig. 2).
The arrest of oligodendrocyte maturation in IL-1b exposed mice
was also apparent at P10 using immunohistochemistry for markers
of immature oligodendrocytes, NG2 and PDGFRa. As previously re-
ported, we observed an increased density of NG2 and PDGFRa po-
sitive cells in the corpus callosum and external capsule (Fig. 3 and
Supp. Fig. 3). Treatment with T4 did not reduce the IL-1b-induced
increases in the numbers of cells expressing NG2 and further sig-
niﬁcantly increased the number of cells expressed PDGFRa in the
IL-1b + T4 treatment group (Fig. 3 and Supp Fig. 3). There was no
change in total numbers of DAPI positive cells in the white matter
in any group (data not shown). Treatment with T4 induced a small
(15%), but signiﬁcant reduction in free T4 levels at P10 in IL-1b-
exposed animals (IL-1b, n = 4 52.0 ± 2.1 vs. IL-1b + T4, n = 6
43.7 ± 1.8 pmol/l). At P30, immunoreactivity of MBP and numbers
of APC positive cells (surrogates for myelination and mature oligo-
dendrocytes, respectively) were reduced by P1–P5 exposure to IL-
1b (Fig. 4). T4 treatment did not increase immunoreactive staining
for MBP in the sensorimotor cortex, nor APC number in the exter-
nal capsule compared with animals exposed only to IL-1b (Fig. 4).4. Discussion
We report that in a model of preterm inﬂammation-induced
white matter injury there was no therapeutic effect of TH
treatment. Speciﬁcally, treatment with T4 (or T3) did not reduce
the maturational blockade of oligodendrocytes nor prevent
Table 1
Systemic inﬂammation induces dysfunction of TH related genes and pathways in oligodendrocytes of the immature brain. Following microarray gene expression analysis the
processed signal intensity values were compared using t-test (p 6 0.05) with a Benjamini-Hochberg multiple testing correction. The gene ID, statistically signiﬁcantly fold change
(red = down-regulation; green = up-regulation), details of gene function and role in white matter injury where applicable are presented.
Gene
name
Change
at P5 
Change
at P10 Gene function
    Receptors & Receptor Interacting proteins
Thra -1.33 -1.22 Thyroid hormone receptor alpha, a nuclear hormone receptor for T3, polymorphisms in which are associated with the magnitude o f white matter lesion in adult neurodegenerative disorders 
Thrb -1.18 NS Thyroid hormone receptor beta, a nuclear hormone receptor for T3 with a specific role in late, hormone-dependent glial & neuronalmaturation 
Trhr -1.51 NS Thyrotropin-releasing hormone receptor, a G protein- coupled rec eptor which binds the tripeptide thyrotropin releasing hormone,  act through phospholipase C to increase intracellular inositol triphosphate 
Trhr2 -1.46 NS Thyrotropin-releasing hormone receptor-2, with a higher basal signaling activity & rapid internalisation kinetics than Trhr 
Cxadr NS +1.50 Coxsackievirus & adenovirus receptor that is essential for tight junction integrity 
Thada -1.87 NS Thyroid adenoma-associated protein that belongs to the death receptor-interacting proteins & a marker of thyroid tissue differe ntiation 
Trip4 -1.25 NS Activating signal co-integrator 1 that is a mediator of nuclear signaling transrepression. 
Trip6 +1.22 NS Thyroid receptor-interacting protein 6, localizes to focal adhesion sites & actin stress fibers to regulate cell migration  
Trip11 -1.15 NS Thyroid receptor-interacting protein-11 that interacts with thrb & thra to specifically increase TH dependent transcription  
Trip13 -1.20 NS Thyroid Hormone Receptor Interactor 13 that plats a key role in chromosome recombination & chromosome structure development during meiosis 
Thrap3 NS -1.15 Thyroid hormone receptor associated protein 3, which is involved in pre -mRNA splicing, mRNA decay & DNA damage responses  
Thrap5 NS -1.27 Thyroid hormone receptor associated protein 5, a co-activator involved in the regulated transcription of nearly all RNA polymer ase II-dependent genes  
    Transporters & Channels 
Slc1a3 NS +1.42 Excitatory amino acid transporter 1 (EAAT, GLAST), which is essential for shaping of excitatory postsynaptic currents & for theprevention of excitotoxic death due to overstimulation of GluRs  
Abcd2 NS +1.98 ATP-binding cassette sub-family D member 2, which is causal in X-linked adrenoleukodystrophy 
Fxyd6 -1.11 +1.26 FXYD domain-containing ion transport regulator 6 that is found in purified myelin 
Mct8  -1.12 +1.30 Specific thyroid cell-membrane transporter, that  stimulates cellular uptake of T4 & T3  
Kcnj10 -1.21 -1.34 ATP-sensitive inward rectifier potassium channel -10 that is important for oligodendrocyte development  
    Cytoskeleton associated factors
Afap1l1 -1.52 -1.37 Actin filament-associated protein 1-like 1 that is possibly involved in podosome & invadosome formation  
Enpp6 -1.52 -1.59 Phosphodiesterase-I alpha/autotaxin that controls cytoskeletal organization & FAK phosphorylation during myelination  
Nefm -1.21 +1.43 Neurofilament medium polypeptide (NF-M) that is required for the development of  axonal caliber & conduction velocity of motor axons
Marcksl1 -1.10 -1.36 Macrophage myristoylated alanine-rich C kinase substrate that is the most prominent cellular substrate for protein kinase C & bindscalmodulin, actin, & synapsin & is a filamentous actin cross-linking protein  
    Enzymes
Dio2 NS NS Type II iodothyronine deiodinase, which stimulates TH signaling by converting the pro-hormone T4 by outer ring deiodination to bioactive T3  
Pygl +1.62 +1.53 Liver glycogen phosphorylase that sustains proliferation & prevents premature senescence in cancer cells  
Hmgcs2 -3.13 +1.48 3-hydroxy-3-methylglutaryl CoA synthase 2, a mitoc hondrial deacetylase that increases ketone body formation that are important for myelination  
Itih3 NS -1.73 Inter-alpha trypsin inhibitor heavy chain 1, which is involved in ECM stabilization & prevention of tumor metastasis  
Gls2 -1.37 NS Mitochondrial glutaminase liver isoform that promotes mitochondrial respiration & increases ATP generation, increases cellular anti-oxidant function & may play a role in preventing tumor proliferation  
Ppm2c NS +1.27 Pyruvate dehydrogenase phosphatase catalytic subunit 1 & deficits in this mitochondrial membrane enzyme are associated with hypomyelination in humans  
    Cell Surface & ECM 
Gpc3 NS -1.28 Cell surface proteoglycan that modulates IGF2 signaling & is critical for regulating cell cycle  
Icosl +5.43 +1.68 Inducible costimulator ligand that is found on Tregs & important for thyroid follicular cell proliferation & differentiation  
Col6a1 NS +1.49 Collagen alpha-1 (VI) chain that is required for Schwann cell differentiation  
Syce2 NS +1.53 Synaptosomal complex central element 2, which acts as a scaffold facilitating chromatid crossover  
    Transcription Factors & Co-factors
Smrte -1.20 -1.31 Silencing mediator for retinoid & thyroid hormone receptors, mediating transcriptional repression by forming complexes that ind uce local chromatin condensation  
Klf9 +1.73 -1.85 Krüppel-like factor 9, zinc finger transcription factor, induced by T3 & required for oligo maturation  
Luzp1 -1.25 -1.39 Leucine zipper protein 1 that possibly down regulates sonic hedgehog ( Shh) expression & is important for neural tube closure  
Cirbp +1.23 NS Cold-inducible RNA-binding protein that is involved in stabilizing transcripts of genes involved in cell survival & that acts as a translational activator  
Hr -1.30 -1.50 Hairless, a transcriptional repressor acting together with Thra/b as an auto regulatory mechanism in TH signaling  
Aldh1a1 NS -1.21 Aldehyde dehydrogenase 1, which is a TH target gene involved in dopaminergic signaling  
    Others
Rbm3 -1.54 NS Putative RNA-binding protein 3, which is stress-inducible, developmentally regulated RNA-binding protein & putative proto-oncogene that is an essential regulator of microRNA biogenesis 
Ler5 +1.36 NS Immediate early response 5 that is a regulator of cell growth & differentiation signals 
Shh +1.58 +2.53 Sonic hedgehog, that induces, via Gli, expression of D3 & decreases T3 availability 
Sult1a1 +2.10 NS Sulfotransferase-1 A1 which reduces the bioavailability of T4, decreasing TH signaling 
98 A.-L. Schang et al. / Brain, Behavior, and Immunity 37 (2014) 95–102hypomyelination in the neonatal period or in adulthood respec-
tively. These observations are important given the continuing
uncertainty over the therapeutic utility of T4 replacement therapyin premature infants (Reuss et al., 1996; Leviton et al., 1999;
Simpson et al., 2005) and the relevance of this animal model to
the preterm population.
Fig. 2. T4 treatment did not prevent IL-1b induced alterations in gene expression of
markers of oligodendrocyte maturation and differentiation. Relative gene expres-
sion of Pdgfra, Cnp, Id2, Mbp, Mag and Mog were assessed by qRT-PCR from O4-
positive cells from P10 mice exposed to PBS (white bars), T4 (light gray bars), IL-1b
(dark grey bars) or IL-1b + T4 (black bars). Results are expressed as the mean ± SEM
from nP 8 per group. Data were compared two by two (each treatment vs. PBS or
IL-1b vs. IL-1b + T4) using the Mann–Whitney test. ⁄p < 0.05; ⁄⁄p < 0.01; ⁄⁄⁄p < 0.001.
Fig. 3. T4 treatment did not prevent the IL-1b induced increase in expression of
oligodendrocyte progenitor markers. Expression of oligodendrocyte progenitors
markers NG2 (A–C) and PDGFRa (D–F) in the cortical white matter of P5 mice
exposed to PBS (white bars), T4 (light gray bars), IL-1b (dark grey bars) or IL-1b + T4
(black bars). NG2 and PDGFRa immunoreactivity in the external capsule (A and D)
(scale bar 10 lm). Quantiﬁcation of NG2 and PDGFRa positive cell number in the
external capsule (B and E) and corpus callosum (C and F). Results are expressed as
the mean ± SEM from nP 4 per group. Asterisks indicate statistically differences
obtained by Mann–Whitney test. ⁄p < 0.05; ⁄⁄⁄p < 0.001.
A.-L. Schang et al. / Brain, Behavior, and Immunity 37 (2014) 95–102 99Exposure to systemic perinatal inﬂammation in this model was
designed to mimic the maturational blockade of oligodendrocytes
and white matter deﬁcits observed in many premature infants.
This is based on the strong clinical associations between prematu-
rity, perinatal maternal/foetal inﬂammation and white matter
damage (Dammann and Leviton, 2004; Wu et al., 2009). Consistent
with our previous data, exposure to inﬂammation induced oligo-
dendrocyte maturational arrest and hypomyelination (Favrais
et al., 2011). The current gene expression data is speciﬁcally from
analysis of puriﬁed pre-oligodendrocytes, as opposed to the whole
cortex gene expression analysis performed previously. This popu-
lation-speciﬁc data conﬁrms and strengthens the previous associa-
tion we have reported between inﬂammation and a blockade of
oligodendrocyte maturation in this model.
Fig. 4. T4 treatment did not prevent the IL-1b induced reduction in myelin or
mature oligodendrocyte markers. Expression of mature oligodendrocyte and myelin
markers MBP (A and B) and APC (C and D) in P30 mice exposed to PBS (white bars),
T4 (light gray bars), IL-1b (dark grey bars) or IL-1b + T4 (black bars). MBP
immunoreactivity (A) and quantiﬁcation (B) within the subcortical white matter
(scale bar 100 lm). APC immunoreactivity (C) and quantiﬁcation (D) in the external
capsule (scale bar 20 lm). Results are expressed as the mean ± SEM from nP 4 per
group. Asterisks indicate statistically differences obtained by Mann–Whitney test.
⁄p < 0.05; ⁄⁄p < 0.01.
100 A.-L. Schang et al. / Brain, Behavior, and Immunity 37 (2014) 95–102Immature mice exposed to IL-1b displayed a transient inﬂam-
mation-induced hypothyroidism. Clinically, hypothyroidism iscommonly associated with chorioamnionitis and prematurity (De
Felice et al., 2005) and there is a strong correlation between low
levels of circulating TH and poor long-term developmental out-
come (Simpson et al., 2005; Williams et al., 2005). Hypothyroidism
in this model was a strong motivation for trialling T4 as a thera-
peutic agent, in addition to the numerous observed changes in
expression of the TH pathway and TH-responsive genes.
The dosage of T4 we used in this study was higher than the
euthyroid dose for preterm infants (8 lg/kg/day over 42 days) (La
Gamma et al., 2009) and identical to that used previously, but
unsuccessfully, to improve long-term behavioural outcomes in a
small clinical trial in preterm infants (Vanhole et al., 1997). The
clinically relevant dose of T4 for the neonatal mouse is unknown,
however the dose used in this study maintains the normal physio-
logical levels of T4 when administered to adult hypothyroid mice
(Rodrigues et al., 2013). Euthyroid treatment is critical as overex-
posure to TH may have negative effects on the brain (Nicholson
and Altman, 1972), and TH repression of TSH can cause hypothy-
roidism upon completion of therapy (La Gamma et al., 2009).
Clinically, treatment with T4 is preferable to T3, as T4 has a consid-
erably higher speciﬁc bioavailability within the brain (Forrest et al.,
1991). However, as a control for the systemic effects of TH such as
those on angiogenesis (Zhang et al., 2010), we also tested T3 in this
model and observed no beneﬁcial effect.
In a model of late-preterm HI insult (P7 rat approximating 32–
36 weeks GA), no reduction in injury was seen when T4 was
administered immediately and at two and four days post-HI at a
dose 10-fold greater than used in this study (200 lg/kg) (Hung
et al., 2013). This supports our data that T4 may have a limited
ability to protect the immature white matter from injury. However,
in the HI study a dose of T4 that is 50-fold higher (1000 lg/kg)
recovered the loss of myelination, but this indicates a dependency
on a supra-clinical dose for neuroprotection (Hung et al., 2013).
Furthermore, we have also previously failed to see improvements
in neuropathology in an excitotoxicity-induced model of perinatal
white matter injury using T3 (Sarkozy et al., 2007). The excitotoxic
model is characterized by microcysts but not oligodendrocyte loss
(Tahraoui et al., 2001), which, like the IL-1b model is also compa-
rable to injury proﬁles seen in contemporary cohorts of preterm in-
fants (Billiards et al., 2008; Buser et al., 2012; Verney et al., 2012).
Altogether these data suggest that there may be an injury- and
age-dependent speciﬁcity to neuroprotection with TH. Neverthe-
less, to comprehensively rule out improvements in brain health
due to TH treatment it will also be necessary to assess facets of
brain development such as neuronal maturation and neurite
outgrowth/synaptogenesis. Cognitive and behavioral testing may
be required to visualize improvements such as these in the gray
matter and to measure any improvements not identiﬁed from
structural assessments of the white matter.
We should also consider that an extended treatment regime
might be necessary to reveal beneﬁcial effects of TH, and whether
the timing of TH treatment in this study mimics in any way that
applied to infants. Clinically, TH is administered to infants pre-ex-
posed to inﬂammation and for 42 days after birth, spanning the
period of maturation of pre-oligodendrocytes into immature-oligo-
dendrocytes (Back et al., 2001). This period of maturation is
approximately P2–P7 in the mouse (Craig et al., 2003), and we
administered TH from P1 to P5, during a great proportion of this
maturational process. Regarding the timing of TH treatment, the
time course of maternal/fetal inﬂammation precipitating prema-
ture birth is poorly understood (Hagberg et al., 2012). However,
inﬂammation discernable from plasma cytokine analyses persists
for at least seven days in preterm infants born with funisitis or cho-
rioamnionitis, and is suggested to be even longer lasting (Leviton
et al., 2011). As such, the inﬂammatory process may be well estab-
lished before initiation of treatment in many cases of preterm
A.-L. Schang et al. / Brain, Behavior, and Immunity 37 (2014) 95–102 101birth. However, any therapy will be required to show efﬁcacy dur-
ing an ongoing inﬂammatory process, suggesting that the timing of
TH treatment in this model is of some clinical relevance. Indeed,
administering TH during inﬂammation in this model may mean
that inﬂammation-induced decreases in TH signalling might have
been substantial enough to abrogate any beneﬁcial effects of T4.
However, although many genes within the TH signaling pathway
are dysregulated by inﬂammation in this model, the speciﬁc fold
changes are moderate (median, 1.2) suggesting that this pathway
is likely to be impaired, but not completely unresponsive to
supplementation. Nevertheless, delayed treatment, and/or combi-
nation therapy with anti-inﬂammatory drugs may be required to
reveal the true neuroprotective potential of TH treatment.
In conclusion, this study suggests that further work is needed to
understand the role of TH in protection/repair across the currently
available animal models of perinatal injury, and in particular with
a focus on the effects of inﬂammation. Importantly, given the pau-
city of experimental research knowledge applicable to the preterm
population, this study also suggests that careful consideration
should be made before additional clinical trials exploring the ther-
apeutic efﬁcacy of TH are initiated. Following a longitudinal study
that suggested improved outcome for early preterm infants(van
Wassenaer et al., 1997), a large double blind randomised clinical
trial was begun in 2012 powered for a priori testing of infant out-
come stratiﬁed by gestational age at birth (Ng et al., 2013). This
new trial with its full assessment of infant outcomes by gestational
age is critical for our understanding of the potential of TH therapy,
as in the original 1997 trial a subgroup of children (those born at
29 weeks) actually had worse behavioural outcomes following TH
treatment (van Wassenaer et al., 2002). Thus caution should be
exercised in assuming that at worst any trial using TH therapy will
ﬁnd limited efﬁcacy. We suggest that any potential for TH treat-
ment to reduce the immense burden of neurological impairment
caused by perinatal brain injury may be unlocked by understand-
ing its role in the context of insult type and severity.Conﬂict of interest
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